Juvenile cancer: Improving care for adolescents and young adults within the frame of medical oncology

Annals of Oncology

Volumn 16, Issue 2, 2005, Pages 181-188

  Pentheroudakis, G ^a   Pavlidis, N ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Adolescents; Cancer; Survival; Treatment; Young adults

Indexed keywords

AFLATOXIN; ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARCINOGEN; CHLORMETHINE; CONTRACEPTIVE AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DIETHYLSTILBESTROL; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; NITROSOUREA DERIVATIVE; PREDNISONE; PROCARBAZINE; VINCRISTINE SULFATE;

ACNE; AGE; ALOPECIA; BODY WEIGHT DISORDER; BONE TUMOR; BRAIN ATROPHY; BRAIN RADIATION; CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COGNITIVE DEFECT; COOPERATION; DEMYELINATION; DOCTOR PATIENT RELATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; FAMILY; FEMUR HEAD NECROSIS; FOLLOW UP; GERM CELL TUMOR; HEART INJURY; HEREDITY; HUMAN; INFERTILITY; INTENSIVE CARE; INTESTINAL FIBROSIS; INTESTINE OBSTRUCTION; LEUKEMIA; LEUKOENCEPHALOPATHY; LIVER TOXICITY; LUNG FIBROSIS; LUNG INJURY; LUNG TOXICITY; LYMPHOMA; MELANOMA; MULTIMODALITY CANCER THERAPY; NEUROPATHIC PAIN; NEUROTOXICITY; NURSING; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; RAYNAUD PHENOMENON; REVIEW; SECOND CANCER; SKIN CARCINOMA; SOCIAL INTERACTION; SOCIAL SUPPORT; SOFT TISSUE SARCOMA; SOLID TUMOR; SURGICAL INJURY; TOOTH DISEASE; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AGE FACTORS; FEMALE; HUMANS; INCIDENCE; INTERPROFESSIONAL RELATIONS; MALE; MEDICAL ONCOLOGY; NEOPLASMS; PATIENT CARE PLANNING; PROGNOSIS; QUALITY OF HEALTH CARE; SURVIVAL; TREATMENT OUTCOME;

EID: 14644430963     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi036     Document Type: Review

References (65)

1. Coleman MP, Babb P Damiecki P et al. Cancer survival trends in England and Wales 1971-1995: deprivation and NHS region. London: HMSO 1999.
2. Bleyer WA. Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival and importance of clinical trials. Med Pediatr Oncol 2002; 38: 1-10.
3. Ries LAG, Eisner MP, Kosary CL et al. SEER cancer statistics review, 1973-1998. Bethesda, MD: National Cancer Institute 2001. http://seer.cancer.gov/Publications/CSR1973_1998/505.
4. Parkin DM, Kramarova E, Draper GJ et al. International Incidence of Childhood Cancer. Vol II, IARC Scientific Publication no 144. Lyon, France: International Agency for Research on Cancer 1998.
5. Birch JM, Alston RD, Kelsey AM et al. Classification and incidence of cancer in adolescents and young adults in England 1979-1997. Br J Cancer 2002; 87: 1267-1274.
6. Smith MA, Gurney JG, Ries LAG. Cancer in adolescents 15-19 years old. In Ries LAG, Smith MA, Gurney JG et al. (eds): Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1997. Bethesda, MD: National Cancer Institute, SEER Program 1999; NIH Pub no 99-4649.
7. Reaman G, Bonfiglio J, Krailo A et al. Cancer in adolescents and young adults. Cancer 1993; 71 (10 Suppl): 3206-3209.
8. Lewis IJ. Cancer in adolescence. Br Med Bull 1996; 52: 887-897.
9. McNally RJQ, Roman E, Cartwright RA. Leukemias and lymphomas: Time trends in the UK, 1984-1993. Cancer Causes Control 1999; 10: 35-42.
10. Martos MC, Winther JF, Olsen JH. Cancer among teenagers in Denmark, 1943-1979. Int J Cancer 1973; 55: 57-62.
11. Quinn M, Babb P, Brock A et al. Cancer Trends in England and Wales, 1950-1999. Studies on Medical and Population Subjects No 66. London: The Stationery Office 2001.
12. Young JL, Wu XC, Roffers SD et al. Ovarian cancer in children and young adults in the United States, 1992-1997. Cancer 2003; 10: 2694-2700.
13. Whyte F, Smith L. A literature review of adolescence and cancer. Eur J Cancer 1997; 6: 137-146.
14. Wu XC, Chen VW, Steele B et al. Cancer incidence in adolescents and young adults in the United States. J Adolesc Health 2003; 6: 405-415.
15. Stiller C. Epidemiology of cancer in adolescents. Med Pediatr Oncol 2002; 3: 149-155.
16. Melnick S, Cole P, Anderson D et al. Rates and risks of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix: An update. N Engl J Med 1987; 316: 514-519.
17. Cuzick J, Szarewski A, Cubie G et al. Management of women who test positive for high risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871-1876.
18. Valagussa P, Bonadonna G. Carcinogenic effects of cancer treatment. In Peckham M, Pinedo H, Veronesi U (eds): Oxford Textbook of Oncology. Oxford: Oxford University Press 1995; 2348-2358.
19. Parkin DM, Kramarova E, Draper GJ et al. International Incidence of Childhood Cancer, Vol II, IARC Scientific Publication No 144. Lyon: International Agency for Research on Cancer 1998.
20. Kramarova E, Stiller CA. The International Classification of Childhood cancer. Int J Cancer 1996; 68: 759-765.
21. Percy C, Van Holten V, Muir C. In Muir C (ed.): International Classification of Diseases for Oncology (ICD-O), 2nd edition. Geneva: World Health Organization 1990.
22. Fritschi L, Coates M, McCredie M. Incidence of cancer among New South Wales adolescents: Which classification scheme describes adolescent cancers better? Int J Cancer 1995; 60: 355-360.
23. Selby P, Bailey C (eds): Cancer and the Adolescent. London: BMJ Publishing Group 1996.
24. Miller BA, Ries LAG, Hankey BF et al. SEER Cancer Statistics Review 1973-1990. NIH Publication No 93-2789. Bethsda, MD: National Institutes of Health 1993.
25. Selby P, Gillis C, Haward R. Benefits from specialised cancer care. Lancet 1996; 348: 313-318.
26. Rauck AM, Fremgen AM, Hutchison CL et al. Adolescent cancers in the United States: A national cancer database (NCDB) report. J Pediatr Hematol Oncol 1999; 21: 310.
27. Nachman J, Sather HN, Buckley JD et al. Young adults 16-21 years of age at diagnosis entered onto Children's Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer 1993; 71 (10 Suppl): 3377-3385.
28. Collette L, Sylvester RJ, Stenning SP et al. Impact of the treating institution on survival of patients with poor prognosis metastatic non seminomatous germ cell tumours. J Natl Cancer Inst 1999; 91: 839-846.
29. Souhami R, Whelan J, McCarhty JF et al. Benefits and problems of an adolescent oncology unit. In Selby P, Bailey C (eds): Cancer and the adolescent. London: BMJ Publishing Group 1996; 276-283.
30. Hollis R, Morgan S. The adolescent with cancer - at the edge of no man's land. Lancet Oncol 2001; 2: 43-48.
31. Whiteson M. The Teenage Cancer Trust - advocating a model for teenage cancer services. Eur J Cancer 2003; 39: 2688-2694.
32. Leonard R, Coleman R, Gregor A et al. Special problems of adolescents with cancer. J Cancer Care 1995; 5: 117-120.
33. Allen R, Newman SP, Souhami RL. Anxiety and depression in adolescent cancer: Findings in patients and parents at the time of diagnosis. Eur J Cancer 1997; 8: 1250-1255.
34. Eiser C. The impact of treatment: Adolescents' views. In Selby P, Bailey C (eds): Cancer and the Adolescent. London, BMJ Publishing Group 1996; 264-275.
35. Trask PC, Paterson AG, Trask CL et al. Parent and adolescent adjustment to pediatric cancer: Associations with coping, social support, and family function. J Pediatr Oncol Nurs 2003; 1: 36-47.
36. Larcombe I, Mott M, Hunt L. Lifestyle behaviours of young adult survivors of childhood cancer. Br J Cancer 2002; 87: 1204-1209.
37. Ettinger RS, Heiney SP. Cancer in adolescents and young adults. Psychosocial concerns, coping strategies, and interventions. Cancer 1993; 71 (10 Suppl): 3276-3280.
38. Schidlow D, Fiel S. Life beyond pediatrics. Transition of chronically ill adolescents from pediatric to adult health care systems. Med Clin North Am 1990; 74: 1113-1120.
39. Barr R. On cancer control and the adolescent. Med Pediatr Oncol 1999; 32: 404-410.
40. Constine LS, Paidas C, Scwartz CL et al. Pediatric solid tumours. In Rubin P (ed.): Clinical Oncology, 8th edition. Philadelphia, PA: WB Saunders 2001; 336-356.
41. Levin VA, Kyritsis AP. Gliomas, medulloblastoma and CNS germ cell tumours. In Cavalli F, Hansen HH, Kaye SB (eds): Textbook of Medical Oncology, 2nd edition. London: M. Dunitz 2000; 493-520.
42. Arai K, Ohta S, Suzuki M et al. Primary immature mediastinal teratoma in adulthood. Eur J Surg Oncol 1997; 23: 64.
43. Kennedy BJ, Loeb V, Peterson V et al. Survival in Hodgkin's disease by stage and age. Med Pediatr Oncol 1992; 20: 100.
44. White L, Seigel SE, Duah TC. Non-Hodgkin's lymphoma in children. II Treatment. Crit Rev Oncol Hematol 1992; 1: 73.
45. Hoeizer D, Thiel E, Loffler H et al. Prognostic factors in a multicentre study for the treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123.
46. Stock W, Sather H, Dodge RK et al. Outcome of adolescents and young adults with ALL: A comparison of Children's Cancer Group and Cancer and Leukemia Group B regimens. Blood 2000; 96: 467a.
47. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Clin Oncol 2001; 19: 3817-3827.
48. Bleyer WA. The adolescent gap in cancer treatment. J Registry Manage 1996; 23: 114-115.
49. Bleyer WA, Tejeda H, Murphy SM et al. National cancer clinical trials: Children have equal success; adolescents do not. J Adolesc Health 1997; 21: 366-373.
50. Rubin P, Williams JP, Slovick FT. Late effects of cancer treatment: Radiation and chemotherapy toxicity. In Rubin P (ed.): Clinical Oncology, 8th edition. Philadelphia, PA: WB Saunders 2001; 897-935.
51. Thompson DE, Mabuchi R, Ron E et al. Cancer incidence in atomic bomb survivors. Part II, Solid tumours, 1958-1987. Radiat Res 1994; 137: S17-S67.
52. Mulhern RK, Tyc VL, Phipps S et al. Health-related behaviours of survivors of childhood cancer. Med Pediatr Oncol 1995; 25: 159-165.
53. Donohue JP, Foster RS. Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am 1998; 25: 461.
54. Kreuser ED, Hetzel WD, Billia DO et al. Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. Cancer Treat Rev 1990; 17: 169-175.
55. Viviani S, Sandoro A, Ragni G et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP versus ABVD. Eur J Cancer 1985; 21: 601.
56. Constine LS, Woolf PD, Cann D et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328: 87.
57. Radford J, Shalet S, Lieberman B. Fertility after treatment for cancer. Questions remain over ways of preserving ovarian and testicular tissue. BMJ 1999; 319: 935.
58. Mulvihill JJ, Myers MH, Connelley R et al. Cancer in offspring of long term survivors of childhood and adolescent cancer. Lancet 1987; 11: 813-817.
59. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
60. Kriesman H, Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol 1992; 19: 508-520.
61. Stover DE, Kaner RJ. Pulmonary toxicity. In De Vita VT, Hellman S (eds): Cancer. Principles and Practice of Oncology, 6th edition. Philadelphia, PA: Lippincott, Williams and Wilkins 2001; 2894-2904.
62. Anderson V, Godber T, Smibert E et al. Neurobehavioural sequelae following cranial irradiation and chemotherapy in children: an analysis of risk factors. Pediatr Rehabil 1997; 1: 63-76.
63. Baker WJ, Royer GL, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991; 9: 679.
64. Van Leeuwen FE, Klokman WJ, Veer MB et al. Long term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487.
65. Valagussa P. Complications of therapy: Long term side effects. In Cavalli F, Hansen HH, Kaye SB (eds): Textbook of Medical Oncology, 2nd edition. London: M. Dunitz 2000; 583-596.